Vitrolife AB (publ) (VTRLY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vitrolife AB (publ) (VTRLY) trades at $9.50 with AI Score 41/100 (Grade C). Vitrolife AB (publ) is a medical device company focused on assisted reproduction. Market cap: $1.29B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for VTRLY: VTRLY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VTRLY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VTRLY: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Vitrolife AB (publ) (VTRLY) Healthcare & Pipeline Overview
Vitrolife AB (publ) is a medical device company specializing in assisted reproduction technologies, offering a comprehensive range of products from oocyte retrieval to cryopreservation. With a global presence and a focus on innovation, Vitrolife serves fertility clinics and laboratories worldwide, addressing the growing demand for advanced IVF solutions.
What Is the Investment Thesis for VTRLY?
Vitrolife operates in the growing assisted reproduction market, driven by increasing infertility rates and advancements in IVF technologies. The company's comprehensive product portfolio and global presence position it to capitalize on this trend. While the company currently has a negative P/E ratio of -2.51 and a negative profit margin of -145.7%, its gross margin of 50.9% indicates potential for improved profitability. Upcoming catalysts include expansion into new geographic markets and the introduction of innovative products like advanced time-lapse systems. However, investors should be aware of the company's high beta of 1.97, indicating higher volatility compared to the market, and the risks associated with operating in a highly competitive industry.
Based on FMP financials and quantitative analysis
VTRLY Key Highlights
Market Cap of $1.29B reflects Vitrolife's position as a key player in the assisted reproduction market.
- Gross Margin of 50.9% demonstrates the company's ability to maintain profitability on its products and services.
- Dividend Yield of 1.18% provides a return for investors.
- Beta of 1.97 indicates higher volatility compared to the market average.
- Presence in Europe, Asia, and the Americas provides a diverse revenue base.
Who Are VTRLY's Competitors?
VTRLY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BRCTF BioArctic AB (publ) | $31.78 | +0.00% | $2.82B | 51 |
| DMPHF Dermapharm Holding SE | $47.69 | +0.00% | $2.36B | 50 |
| GNNDY GN Store Nord A/S | $41.98 | -8.62% | $2.04B | 44 |
| HBMHF HBM Holdings Limited | $1.56 | +0.00% | $1.30B | 53 |
| HTSUF Hisamitsu Pharmaceutical Co., Inc. | $29.00 | +0.00% | $2.04B | 48 |
| IART Integra LifeSciences Holdings Corporation | $16.59 | -3.77% | $1.29B | 61 |
| IRMD IRadimed Corporation | $87.30 | -0.11% | $1.12B | 95 |
| SILK Silk Road Medical, Inc | $27.49 | -0.04% | $1.12B | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VTRLY's Key Strengths?
Comprehensive product portfolio covering the entire IVF process.
- Global presence with operations in key markets.
- Strong focus on innovation and technological advancements.
- Established relationships with fertility clinics and IVF laboratories.
What Are VTRLY's Weaknesses?
Negative profit margin and P/E ratio.
- High beta indicating higher volatility.
- Dependence on the assisted reproduction market.
- Exposure to regulatory changes and ethical concerns.
What Could Drive VTRLY Stock Higher?
VTRLY catalyst: Expansion into new geographic markets, particularly in emerging economies with growing demand for IVF treatments.
- Development and launch of advanced time-lapse systems with improved embryo monitoring and selection capabilities.
- Strategic acquisitions of companies with complementary technologies to expand product offerings and market reach.
- Increasing adoption of cryopreservation services and fertility preservation solutions.
- Positive clinical trial results or regulatory approvals for new products or technologies.
What Are the Key Risks for VTRLY?
Financial-distress signal — its Altman Z-Score of 0.57 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-53.3%) — the business is not currently generating profit on shareholder capital.
- Intense competition from other medical device companies in the assisted reproduction market.
- Economic downturns affecting the affordability of IVF treatments and demand for Vitrolife's products.
- Regulatory changes impacting the assisted reproduction market, such as restrictions on certain procedures or technologies.
- Ethical concerns and societal perceptions of IVF affecting public acceptance and demand.
- Currency fluctuations impacting the value of the ADR for U.S. investors.
What Are the Growth Opportunities for VTRLY?
- Expanding into Emerging Markets: The increasing awareness and acceptance of IVF treatments in emerging markets, such as India, China, and Brazil, present a significant growth opportunity for Vitrolife. These regions have a large population base and rising disposable incomes, driving demand for assisted reproduction services. By establishing partnerships with local clinics and distributors, Vitrolife can expand its market share and revenue streams in these high-growth regions. Timeline: Ongoing.
- Developing Advanced Time-Lapse Systems: Vitrolife's EmbryoScope and Primo Vision time-lapse systems offer enhanced embryo monitoring and selection capabilities. Investing in the development of next-generation time-lapse technologies with improved image resolution, AI-powered analysis, and user-friendly interfaces can further differentiate Vitrolife from competitors. This can lead to increased adoption by fertility clinics seeking to improve IVF success rates. Market size: The global time-lapse microscopy market is projected to reach $350 million by 2028. Timeline: 2-3 years.
- Offering Integrated Digital Solutions: Integrating its product portfolio with digital solutions, such as cloud-based data management, remote monitoring, and AI-powered decision support tools, can enhance Vitrolife's value proposition. These solutions can streamline workflows, improve data analysis, and facilitate collaboration between fertility clinics and patients. This can drive customer loyalty and attract new clients seeking comprehensive IVF solutions. Timeline: 1-2 years.
- Acquiring Complementary Technologies: Acquiring companies with complementary technologies, such as genetic testing platforms, sperm analysis tools, or fertility tracking apps, can expand Vitrolife's product offerings and strengthen its position in the assisted reproduction market. Strategic acquisitions can provide access to new customer segments, enhance R&D capabilities, and create synergies across the company's portfolio. Timeline: Ongoing.
- Expanding Cryopreservation Services: Cryopreservation, the process of freezing and storing eggs, sperm, or embryos, is an increasingly important component of IVF treatments. Vitrolife can expand its cryopreservation services by offering advanced freezing techniques, improved storage solutions, and comprehensive training programs for fertility clinics. This can drive revenue growth and enhance Vitrolife's reputation as a leader in fertility preservation. Market size: The global cryopreservation market is projected to reach $7 billion by 2027. Timeline: 1 year.
What Are VTRLY's Competitive Advantages?
- Specialized product portfolio: Vitrolife offers a comprehensive range of products specifically designed for assisted reproduction, creating a barrier to entry for general medical device companies.
- Established relationships with fertility clinics: Vitrolife has built strong relationships with fertility clinics worldwide, providing a reliable customer base.
- Technological expertise: Vitrolife's focus on innovation and development of advanced technologies, such as time-lapse systems, provides a competitive edge.
- Global presence: Vitrolife's operations in multiple regions provide diversification and access to different markets.
What Does VTRLY Do?
Vitrolife AB (publ) was founded in 1994 in Gothenburg, Sweden, initially named Scandinavian IVF Science before rebranding in 1998. The company focuses on developing, producing, and marketing medical devices and products for assisted reproduction. Vitrolife's offerings span the entire IVF process, including oocyte retrieval needles, sperm processing solutions, in vitro fertilization media and oil, micromanipulation pipettes, and labware. They also provide incubators, cryopreservation solutions, and preimplantation genetic testing products. Vitrolife has expanded its product line to include advanced systems like EmbryoScope and Primo Vision time-lapse systems, along with associated time-lapse dishes and evaluation tools. The company also offers Octax laser and imaging systems, as well as log and guard systems and wireless sensors for laboratory monitoring. Vitrolife operates globally, with a presence in Europe, the Middle East, Africa, Asia, Japan, the Pacific region, and North and South America. Vitrolife's evolution has been marked by a commitment to innovation and a focus on providing comprehensive solutions for fertility clinics. With a workforce of 1150 employees, the company continues to invest in research and development to enhance its product portfolio and address the evolving needs of the assisted reproduction market.
What Products and Services Does VTRLY Offer?
- Develops and produces medical devices for assisted reproduction.
- Markets products for in vitro fertilization (IVF).
- Provides oocyte retrieval needles for egg harvesting.
- Offers sperm processing solutions for male infertility.
- Supplies IVF media and oil for embryo culture.
- Manufactures micromanipulation pipettes for embryo manipulation.
- Offers labware and incubators for IVF labs.
- Provides cryopreservation solutions for freezing eggs, sperm, and embryos.
How Does VTRLY Make Money?
- Develops and manufactures medical devices and consumables for assisted reproduction.
- Sells products directly to fertility clinics and IVF laboratories.
- Generates revenue through product sales and service contracts.
- Invests in research and development to innovate new products and improve existing ones.
What Industry Does VTRLY Operate In?
Vitrolife operates within the medical device industry, specifically focusing on the assisted reproduction technology (ART) sector. The ART market is experiencing growth due to rising infertility rates, delayed pregnancies, and increasing acceptance of IVF treatments globally. Competition includes companies offering similar IVF products and services. Vitrolife differentiates itself through its comprehensive product portfolio, including advanced imaging and time-lapse systems. The industry is also subject to regulatory oversight and technological advancements, requiring companies to continuously innovate and adapt to changing standards.
Who Are VTRLY's Key Customers?
- Fertility clinics.
- IVF laboratories.
- Hospitals with reproductive medicine departments.
- Research institutions studying reproductive biology.
Vitrolife AB (publ) Financial Trajectory
Vitrolife AB (publ) (VTRLY) reported $857.0M in revenue for Q2 2026, reflecting 6.2% growth compared to the prior quarter. The company recorded net income of $129.0M, with diluted EPS of $0.95. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, VTRLY averaged $-9.20 in diluted EPS.
Company Profile
Vitrolife AB (publ) operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Gothenburg, SE. The company is led by CEO Bronwyn Brophy O'Connor. VTRLY has traded publicly since 2016.
How Vitrolife AB (publ) Is Valued
Vitrolife AB (publ) carries a market capitalization of $1.29B, placing it in the small-cap category. Relative to its peer group, VTRLY's quantitative score of 41/100 is roughly in line with the peer average of 49/100.
Key Financial Metrics
Return on equity for Vitrolife AB (publ) stands at -53.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -44.1%, showing how much profit it generates from its asset base. Its free cash flow yield is 4.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.64 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -40.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Vitrolife AB (publ)'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.57 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Vitrolife AB (publ) revenue of about $3.46B for fiscal 2026, with EPS near $0.00. The estimate reflects 5 contributing analysts.
VTRLY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Comprehensive product portfolio covering the entire IVF process.
- Global presence with operations in key markets.
- Strong focus on innovation and technological advancements.
- Established relationships with fertility clinics and IVF laboratories.
Bear Case
- Negative profit margin and P/E ratio.
- High beta indicating higher volatility.
- Dependence on the assisted reproduction market.
- Exposure to regulatory changes and ethical concerns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $857M | $129M | $0.95 |
| Q1 2026 | $807M | $101M | $0.74 |
| Q4 2025 | $891M | -$5.31B | -$39.24 |
| Q3 2025 | $823M | $101M | $0.74 |
Based on FMP financials and quantitative analysis
VTRLY Latest News
No recent news available for VTRLY.
VTRLY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VTRLY.
Price Targets
Wall Street price target analysis for VTRLY.
VTRLY MoonshotScore
What does this score mean?
The MoonshotScore rates VTRLY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Bronwyn Brophy O'Connor
CEO
Bronwyn Brophy O'Connor is the CEO of Vitrolife AB (publ). Information regarding her detailed career history, education, and previous roles is not available in the provided data. As CEO, she is responsible for leading the company's strategic direction, overseeing operations, and driving growth in the assisted reproduction market. She manages a workforce of 1150 employees.
Track Record: Details regarding Bronwyn Brophy O'Connor's specific achievements, strategic decisions, and company milestones under her leadership are not available in the provided data. Her role involves guiding Vitrolife's expansion, fostering innovation, and maintaining its position in the competitive IVF market.
Vitrolife AB (publ) ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. VTRLY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without the same stringent SEC reporting requirements as listed companies. This allows U.S. investors to invest in Vitrolife without directly dealing with foreign markets.
- Home Market Ticker: Nasdaq Stockholm, Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: VTRL
VTRLY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Vitrolife (VTRLY) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors and carry a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure: The lack of publicly available financial information makes it difficult to assess the company's financial health and performance.
- Lower liquidity: Trading volume may be limited, leading to wider bid-ask spreads and potential price volatility.
- Regulatory uncertainty: OTC-traded companies may be subject to less regulatory oversight compared to exchange-listed companies.
- Potential for fraud or manipulation: The OTC market has a higher risk of fraudulent or manipulative activities.
- Information scarcity: It may be difficult to find reliable information about the company and its operations.
- Verify the company's legal registration and business licenses.
- Obtain and review any available financial statements.
- Research the background and experience of the company's management team.
- Assess the company's competitive position and market opportunities.
- Understand the company's business model and revenue streams.
- Evaluate the risks associated with investing in the company.
- Consult with a qualified financial advisor.
- Established operating history since 1994.
- Global presence with operations in multiple regions.
- Focus on a specialized market (assisted reproduction).
- Products are used by medical professionals in fertility clinics.
- ADR listing, even at Level 1, suggests some level of compliance.
Vitrolife AB (publ) Healthcare Stock: Key Questions Answered
What does the AI Score mean for VTRLY?
VTRLY holds an AI Score of 41/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Vitrolife AB (publ) is a medical device company focused on assisted reproduction. The company develops, produces, and markets products for in vitro fertilization and related treatments globally.
What does Vitrolife AB (publ) do?
Vitrolife AB (publ) is a medical device company specializing in assisted reproduction technologies. It develops, produces, and markets a comprehensive range of products used in in vitro fertilization (IVF) and other fertility treatments. These products include oocyte retrieval needles, sperm processing solutions, IVF media, micromanipulation pipettes, labware, incubators, cryopreservation solutions, and advanced systems like time-lapse incubators.
What do analysts say about VTRLY stock?
Analyst coverage of VTRLY stock is limited due to its OTC listing. However, the company's position in the growing assisted reproduction market and its comprehensive product portfolio are generally viewed positively. Key valuation metrics, such as the negative P/E ratio and profit margin, raise concerns about current profitability.
What are the main risks for VTRLY?
The main risks for VTRLY include intense competition in the assisted reproduction market, economic downturns affecting demand for IVF treatments, regulatory changes impacting the industry, and ethical concerns surrounding IVF. As an OTC-traded company, VTRLY also faces risks related to limited financial disclosure, lower liquidity, and potential for fraud or manipulation.
What are the key factors to evaluate for VTRLY?
Vitrolife AB (publ) (VTRLY) holds an AI score of 41/100 (low). Vitrolife operates in the growing assisted reproduction market, driven by increasing infertility rates and advancements in IVF technologies. Not financial advice.
How frequently does VTRLY data refresh on this page?
VTRLY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VTRLY's recent stock price performance?
Vitrolife AB (publ) (VTRLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive product portfolio covering the entire IVF process. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VTRLY overvalued or undervalued right now?
Vitrolife AB (publ) (VTRLY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VTRLY before investing?
Before investing in Vitrolife AB (publ) (VTRLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-traded companies.
- Financial data may not be fully up-to-date.
- Analyst coverage is limited.